Skip to main content

Table 2 The clinical trials exploring the efficacy of α-PD-1/PD-L1 plus chemotherapy

From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Clinical trial

Phase

α-PD-1/PD-L1

Chemotherapy

Cancer type

Primary outcome measures

NCT02039674

1/2

Pembrolizumab

Pemetrexed and carboplatin

Non-squamous NSCLC

ORR

NCT02775435

3

Pembrolizumab

Paclitaxel/nab-paclitaxel and carboplatin

Squamous NSCLC

PFS, OS

NCT02819518

3

Pembrolizumab

Paclitaxel; nab-paclitaxel;

gemcitabine and carboplatin

TNBC

PFS, OS

NCT03189719

3

Pembrolizumab

Cisplatin and 5-fluorouracil

Esophageal or GEJ cancer

PFS, OS

NCT03615326

3

Pembrolizumab

Trastuzumab plus either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin

HER2+ gastric or GEJ adenocarcinoma

PFS, OS

NCT02872116

3

Nivolumab

5-fluorouracil and leucovorin plus oxaliplatin; capecitabine and oxaliplatin

Gastric cancer, esophageal or GEJ adenocarcinoma

PFS, OS

NCT03607539

3

Sintilimab

Pemetrexed and platinum

Non-squamous NSCLC

PFS

NCT03629925

3

Sintilimab

Gemcitabine and platinum

Squamous NSCLC

PFS

NCT03134872

3

Camrelizumab

Carboplatin and pemetrexed

Non-squamous NSCLC

PFS

NCT03707509

3

Camrelizumab

Gemcitabine and cisplatin

Nasopharyngeal carcinoma

PFS

NCT03594747

3

Tislelizumab

Paclitaxel/nab-paclitaxel and carboplatin

Squamous NSCLC

PFS

NCT03663205

3

Tislelizumab

Platinum and pemetrexed

Non-squamous NSCLC

PFS

NCT02366143

3

Atezolizumab

Bevacizumab plus paclitaxel and carboplatin

Non-squamous NSCLC

PFS, OS

NCT02763579

3

Atezolizumab

Carboplatin and etoposide

SCLC

PFS, OS

NCT02425891

3

Atezolizumab

Nab-paclitaxel

TNBC

PFS, OS

NCT02367781

3

Atezolizumab

Carboplatin and nab-paclitaxel

Non-squamous NSCLC

PFS, OS

NCT03043872

3

Durvalumab

Etoposide and carboplatin/ cisplatin

SCLC

OS

  1. Abbreviations: NSCLC non-small cell lung cancer, ORR objective response rate, PFS progression-free survival, OS overall survival, GEJ gastroesophageal junction, SCLC small cell lung cancer